On Demand 2023 Thursday Program

You can earn up to 7.25 AMA PRA Category 1 Credit(s)TM.

Price: FREE for meeting attendees who purchased a ticket to the Thursday Program, otherwise $99 members, $125 non-members

This year’s Thursday Program will feature the latest developments in the science, diagnosis, and therapeutics for mast cell diseases and anaphylaxis.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Identify receptors and signaling molecules in mast cells that can be targeted for therapeutics.
  • Discuss novel insights into mechanisms of action for drug allergies.
  • Describe the genetics of tryptase and how copy number variations in this gene can lead to clinical findings.
  • Define current nomenclature for mast cell diseases.
  • Review the differential diagnosis for patients with idiopathic anaphylaxis.
  • Describe therapeutic options for patients with recurrent anaphylaxis and mast cell diseases.
  • Develop a plan for formal diagnosis of alpha-gal allergy, including how best to perform oral challenges and how to manage patients with alpha-gal allergy in less common clinical scenarios, such as if they need a prosthetic valve.
  • Recite and discuss risk factors for fatal anaphylaxis and incidence of fatal outcomes.
  • Consider a risk-stratification model when diagnosing patients with food allergies.
  • Review updates to the newest U.S. anaphylaxis practice parameters.
  • Discuss data on the effect of epinephrine when administered to healthy controls as well as patients undergoing an allergic reaction and why it is recommended as first line therapy for anaphylaxis.
  • Describe how to improve outcomes of anaphylaxis in the community setting and identify where anaphylaxis occurs in the community.
  • Compare the current data on epinephrine when given by intranasal or sublingual route versus when given by intramuscular route.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Attendance
  • 7.25 CBRN
Course opens: 
Course expires: 

Jay A. Lieberman, MD, FACAAI
Dana V. Wallace, MD, FACAAI
Lawrence B. Schwartz, MD, PhD, FACAAI
Marianna C. Castells, MD, PhD, FACAAI
Jonathan J. Lyons, MD
Joseph Butterfield, MD
Thomas A. E. Platts-Mills, MD, PhD, FACAAI
Matthew P. Giannetti, MD
Scott P. Commins, MD, PhD
Paul Turner, PhD
Matthew C. Greenhawt, MD, MBA, MSc, FACAAI
David BK Golden, MD, FACAAI

Available Credit

  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Attendance
  • 7.25 CBRN


Please login or create an account to take this course.